SCHEMBL23769155

SCHEMBL23769155

CCOC(=O)c1cn(Cc2ccc(N3CC4CC4C3)nc2F)nn1

nearest known ligand 0.50

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.50
LMNA P02545 1/20 0.50
KLKB1 P03952 3/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
HPGD P15428 1/20 0.47
BTK Q06187 6/20 0.45
GLA P06280 1/20 0.41
MAPK1 P28482 2/20 0.41
MEN1 O00255 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
TP53 P04637 1/20 0.38
POLB P06746 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31033209 0.91 KLKB1 (0.56) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL20541015 0.91 KLKB1 (0.56) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL30027310 0.89 ALDH1A1 (0.52) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL23769187 0.89 ALDH1A1 (0.52) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL23769282 0.89 ALDH1A1 (0.49) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL23753965 0.89 ALDH1A1 (0.52) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL29906565 0.89 KLKB1 (0.47) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL23768891 0.89 KLKB1 (0.47) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL18815297 0.89 BTK (0.58) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD
SCHEMBL23768900 0.89 ALDH1A1 (0.48) ALDH1A1LMNAKLKB1SMN1; SMN2HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2023-09-19 US disclosed
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-09-23 US disclosed
WO-2021160718-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2021-08-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210292301-A1 HETEROAROMATIC CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS KLKB1, KLK5, KLK1 ALDH1A1 1223/4885LMNA 2081/4885KLKB1 1/4885
US-11760745-B2 Heteroaromatic carboxamide derivatives as plasma kallikrein inhibitors KLKB1, KLK5, KLK1 ALDH1A1 1223/4885LMNA 2081/4885KLKB1 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.